Objective: We compared the risk of cardiovascular disease (CVD) and all-cause mortality in subgroups of pre-diabetes defined by fasting plasma glucose (FPG), 2-hour plasma glucose (2hPG) or HbA1c.
In 1979-1980, the world health organization (WHO), the American Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD), and other diabetes organisations made a common agreement regarding the diagnostic criteria for diabetes and impaired glucose tolerance (IGT) based on the oral glucose tolerance test (OGTT) (1, 2). Since then, the diagnostic criteria for diabetes and pre-diabetes have changed several times, and there is currently no consensus on the definition of pre-diabetes between the different organisations worldwide (3) (4) (5) . It is generally accepted that diabetes and pre-diabetes can be diagnosed on the basis of measures of fasting plasma glucose (FPG), 2-hour plasma glucose (2hPG) after an OGTT, or by using haemoglobin A1c (HbA1c). In clinical practice, FPG and HbA1c are preferred over the OGTT which is inconvenient, less reproducible, and more costly. However, the cutpoints for FPG and HbA1c vary by the different organisations. In 2003, ADA suggested to lower the cut-point for impaired fasting glycaemia (IFG) from 6.1 mmol/L (110 mg/dl) to 5.6 mmol/L (100 mg/dl) (6) in order to capture more individuals with IGT without performing an OGTT.
The sensitivity for identifying IGT was increased with the new lower criterion for fasting glucose, but it also resulted in a two-to four fold increase in the prevalence of IFG across countries (7) . Furthermore, with the lower cut-off, the overall incidence rate for diabetes among people with IFG was greatly reduced (8) . This observation together with a lack of evidence for a reduction in adverse outcomes among these newly defined individuals with IFG, have led the WHO not to adopt the lower cut-off for IFG (3).
More recently, HbA1c was recommended for the diagnosis of diabetes by both ADA and WHO (9, 10) . However, in terms of identifying individuals with pre-diabetes or intermediate hyperglycaemia, the two organisations again differed in their recommendations. While ADA now recommends using HbA1c in the range of 5.7-6.4% (39-47 mmol/mol) for defining prediabetes, WHO has not yet adopted HbA1c for diagnosing intermediate hyperglycaemia/pre-diabetes (9) . The International Expert Committee (IEC), in turn, acknowledges the elevated risk of progression to diabetes associated with increasing HbA1c levels and recommends initiation of prevention strategies in individuals with HbA1c levels in a narrower range of 6.0-6.4% (42-47 mmol/mol) (11) .
In addition to increasing risk of diabetes, both fasting glucose and HbA1c levels in the range of pre-diabetes are associated with increased risk of cardiovascular disease (CVD) and mortality (12, 13) . However, large inconsistencies between studies have been observed due to the use of different cut-points and reference groups (14) , and direct comparisons between the associations of different glucose and HbA1c criteria with development of CVD and/or mortality within the same population are sparse (15) . In the ongoing Whitehall II study we therefore compared the risk of fatal or non-fatal CVD or all-cause mortality in individuals with pre-diabetes identified by FPG, 2hPG or HbA1c using the cut-points suggested by ADA versus WHO/IEC. Additionally, we examined the associations of continuous pre-diabetic levels of FPG, 2hPG or HbA1c with the 10-year risk of CVD or mortality.
Research Design and Methods

Study Design and Participants
The prospective cohort study is based on participants from the Whitehall II study, which is an occupational cohort of 10,308 British civil servants (6,896 men, 3,412 women) initially recruited in 1985. The study population has been followed with clinical examinations every five years. This study is based on phase 7 (2002-04) and phase 9 (2007-09) where FPG, 2hPG and HbA1c were measured, excluding participants with known diabetes. The study population consists of the 5,427 participants with complete information on both HbA1c and FPG (87% of them also had 2hPG measured). All the included participants had been fasting ≥8 hours.
Ethics
The University College London Ethics Committee reviewed and approved the study. Written informed consent was obtained from all participants at each study phase. The Whitehall II study is described in detail elsewhere (16, 17) .
Definition of pre-diabetes
At each study phase the participants had a standard 75-g OGTT with measurement of plasma glucose in the fasting state and after 120 min. HbA1c was also measured. Pre-diabetes was defined according to the WHO/IEC criteria as FPG 6.1-6.9 mmol/L and/or HbA1c 6.0-6.4%
(42-47 mmol/mol) and according to the ADA criteria as FPG 5.6-6.9 mmol/L and/or HbA1c 5.7-6.4% (39-47 mmol/mol). For 2hPG, we defined pre-diabetes as 7.8-11.0 mmol/L according to the definition by WHO and ADA. Normoglycaemia was defined as values below the cutpoints for pre-diabetes for each diagnostic criterion.
Assessment of clinical characteristics
At all clinical examinations, measurements of anthropometry and handling of blood samples were carried out according to standard protocols (16) . Plasma glucose concentrations were measured by the glucose oxidase method (17) . HbA1c was measured in whole blood, drawn into EDTA Monovette tubes, using the validated (18) Tosoh G8 high performance ion exchange liquid chromatography platform (Tosoh Bioscience, Tessenderlo, Belgium). Information on medication, family history of diabetes, smoking and alcohol intake was obtained from questionnaire.
Outcome ascertainment
Outcome was defined as a composite endpoint of CVD or death. The participants' unique National Health Service (NHS) identification numbers were linked to the NHS Hospital Episode Statistics database (19) . Incidence of CVD was assessed over the follow-up period from 2002-04 to end of follow-up (30 th June 2015) and included fatal and non-fatal coronary heart disease (defined by the ICD-9 codes 410-414 or ICD-10 codes I20-25) and stroke. Nonfatal myocardial infarction was determined using data from questionnaires, study electrocardiograms (ECGs), hospital acute ECGs, cardiac enzymes, and physician records (16) .
In the definition of stroke, cases identified by self-report only were excluded. Stroke included first subarachnoid haemorrhage, cerebral infarction, intra-cerebral haemorrhage, not specified stroke (ICD-10 codes I60-I64), and transient cerebral ischaemic attacks (ICD-10 code G45).
Cases of stroke were ascertained from participants' general practitioners, by information extracted from hospital medical records, or from the NHS Hospital Episode Statistics database.
Cardiovascular event ascertainment in the Whitehall II study has recently been validated (20) .
All-cause mortality was assessed from 2002-04 to end of follow-up by flagging participants at the NHS Central Registry, which provided information on the cause and date death. for the non-constant effect of age over time on CVD risk and mortality, the follow-up period of each participant was split into 1-year age bands prior to analysis.
Statistical analysis
We performed two sensitivity analyses: 1) We repeated the analyses using only fatal and nonfatal CVD events as outcome (constituting 65% of the composite events) and censoring the study participants at time of death; 2) In a subset with complete information on FPG, HbA1c and 2hPG levels (n=4,730), we expanded the analyses to include pre-diabetes by 2hPG (i.e.
IGT).
We further calculated the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for the 10-year risk of an event for each pre-diabetes subgroup. We also estimated the 10-year risk of an event across the prediabetic range of glycaemia by the ADA criteria using Poisson regression analysis with models fitted separately for FPG, 2hPG and HbA1c. In the models, the glycaemic measure was specified with natural cubic splines with three knots to facilitate detection of a potential inflection point in the associations.
Statistical analyses were performed in R version 3.2.3 (The R Foundation for Statistical
Computing, www.R-project.org) and SAS version 9.4 (SAS Institute, Cary, NC, USA).
Results
Pre-diabetes by different definitions
Using the WHO/IEC criteria, 402 (7.4%) of the 5,427 participants in the study population had pre-diabetes by the FPG criterion and 288 (5.3%) by the HbA1c criterion (n=628 in total, Figure S1 for further details).
Thus, the proportion of individuals with pre-diabetes was more than 3-fold higher using the ADA criterion compared to the WHO/IEC criterion. Applying the ADA criteria in the subset of the 4,730 individuals with full data on FPG, 2hPG and HbA1c, 26.6% had pre-diabetes by FPG, 15.8% by HbA1c and 14.2% by 2hPG.
For both WHO/IEC-and ADA-defined pre-diabetes, individuals identified by FPG levels only were more likely to be men and to report a higher amount of alcohol consumption than those identified by HbA1c ( Table 1) . Those identified by HbA1c only were more likely to be of nonWhite ethnicity, they were older, and had lower levels of total cholesterol, LDL cholesterol, and blood pressure than those identified by FPG levels only. However, those identified by HbA1c were more likely to have had a previous CVD event and to be in antihypertensive-and/or lipid-lowering treatment (Tables 1).
Event rates in individuals with pre-diabetes by different definitions
Overall event rates: Median (IQR) follow-up time for a CVD or mortality event was 11.5 (8.9;12.1) years. During follow-up, 134 (21.3%) individuals with pre-diabetes by WHO/IEC FPG or HbA1c criteria developed CVD or died. The corresponding number was 370 (18.5%) in the ADA pre-diabetes group. With the WHO/IEC criteria, the incidence rate of an event in those with pre-diabetes was 22.7 per 1000-PY which was 54% higher than in individuals with normoglycaemia ( Table 2 ). The higher incidence rate in the pre-diabetes group was stable towards adjustment for age, sex and ethnicity, but decreased to 17% and became non-significant after adjustment for previous CVD, smoking, total cholesterol, HDL-cholesterol, systolic blood pressure, and use of antihypertensive treatment. Using the ADA criteria, the incidence rate for the prediabetic group was somewhat lower at 18.9 per 1000-PY, which was 37% higher compared with the normoglycaemic group, and decreasing to only 12% higher (non-significant)
in the fully adjusted model ( Table 2) .
Event rates by glycaemic criteria: Kaplan-Meier survival curves for an event for individuals with pre-diabetes versus normoglycaemia by different glycaemic criteria are shown in Figure   1 , whereas rates and rate ratios are shown in Table 1 . In individuals defined as having prediabetes by FPG levels (without taking the HbA1c level into account), the rate of an event was
19.4 for FPG levels 6.1-6.9 mmol/L (WHO criteria) and 16.5 for FPG levels 5.6-6.9 mmol/L (ADA criteria) ( Figure 1A and Table 2 ). In the fully adjusted model, the incidence rates were at the same level as that of the normoglycaemic group for both the WHO and ADA criteria ( Table 2) .
Among individuals with pre-diabetes by HbA1c levels (without taking the FPG level into account), the incidence rate was 29.5 for HbA1c levels 6.0-6.4% (IEC criteria) and 26.0 for HbA1c levels 5.7-6.4% (ADA criteria) ( Figure 1B and Table 2 ), which was around twice that of the rate in the normoglycaemic group for both the WHO and ADA criteria. Adjustment for age, sex and ethnicity decreased the excess in incidence rate to around 50%, and additional adjustment reduced it further to an excess of 13-17% (non-significant) ( Table 2) .
Analyses limiting the outcome to only include CVD-related events confirmed the associations reported above (Supplementary Table S1 ).
In the sensitivity analysis including only individuals with 2hPG measurements, the rate for prediabetes by 2hPG was 19.3 which was 44% higher compared with the normoglycaemic group (< 7.8 mmol/L). Upon confounder adjustment there was no excess risk associated with prediabetes ( Table 2 and Supplementary Figure S2 ).
Comparing event rates between non-overlapping groups: The incidence rate of an event in individuals with pre-diabetes by FPG levels 5.6-6.0 mmol/L but normal HbA1c levels (< 5.7%) was low and comparable to that of the normoglycaemic group (FPG < 5.6 mmol/L and HbA1c < 5.7%) (~13 per 1000-PY, Supplementary Figure S3 ). In contrast, the incidence rate in people 
Performance of the different glycaemic criteria
The sensitivity and PPV for the 10-year risk of an event were low for all the pre-diabetes subgroups (Supplementary Table S2 ). Using the ADA criteria for FPG and HbA1c more than doubled the sensitivity but decreased the specificity compared to the WHO/IEC criteria. The PPV was higher for pre-diabetes defined by HbA1c than by FPG or 2hPG, whereas the NPV was similar across all the pre-diabetes subgroups.
Exploring event rates by increasing levels of glycaemia
The 10-year absolute risk of an event across the pre-diabetic range by the ADA criteria for FPG, 2hPG and HbA1c is shown in Figure 2 . The risk was higher for all levels of HbA1c, whereas for FPG and 2hPG the risk across the pre-diabetic range was somewhat comparable. There was no indication of an inflection point for any of the glycaemic measures.
Conclusions
In the present large prospective Whitehall II cohort study of adults aged 50-80 years with simultaneous measures of different glycaemic measures, we found that the prevalence of prediabetes defined by FPG and/or HbA1c was three times higher when the ADA criteria were used compared with the WHO/IEC definitions. Individuals with pre-diabetes defined by HbA1c had substantially higher risk of CVD and mortality than those defined by the FPG or 2hPG criteria irrespective of whether the cut-point of 5.7% (39 mmol/mol) or 6.0% (42 mmol/mol) was used.
For none of the glycaemic measures did we find an inflection point for risk of CVD and mortality over the pre-diabetic range. Furthermore, the excess risk of CVD and death associated with having pre-diabetes was greatly reduced in HbA1c-defined pre-diabetes and null in FPGand 2hPG-defined pre-diabetes after adjustment for demographic and cardiovascular risk factors. These findings indicate that there is no obvious optimal glycaemic cut-off for risk stratification, and the higher risk for CVD and death among individuals with pre-diabetes is mainly explained by its clustering with other risk factors associated with hyperglycaemia. This challenges the use of the pre-diabetes classification as a stand-alone tool for risk stratification among older adults.
Only a few previous studies have compared different definitions of pre-diabetes in relation to CVD and mortality in the same population (15, 22) . Warren et al. found in the prospective Atherosclerosis Risk in Communities (ARIC) study that HbA1c was more specific and provided better risk discriminating regarding future major events than FPG or 2hPG concentrations. After adjustment for cardiovascular risk factors, the risk of all-cause mortality was reduced but still significantly elevated in those with HbA1c-defined pre-diabetes. However, incidence rates for cardiovascular mortality became non-significant for all pre-diabetic subgroups after adjustment for cardiovascular risk factors (15) , which is in accordance with the findings from our analysis and underscores the importance of focusing on non-glycaemic risk factors in individuals with pre-diabetes. In contrast to the ARIC study, we also reported absolute 10-year risk estimates over the pre-diabetic range of all the three glycaemic measures, and these showed a higher absolute risk for HbA1c than for FPG and 2hPG concentrations. We found no inflection point of risk in the association which is in line with the findings from the population-based Australian Diabetes, Obesity and Lifestyle (AusDiab) study (13) . Secondly, we evaluated the risk associated with different combinations of HbA1c and FPG levels, which enabled us to show that pre-diabetic HbA1c levels are associated with elevated risk of CVD and death even when FPG levels are normal, while the opposite is not the case (i.e. pre-diabetic FPG and normal HbA1c levels). In support of this finding, data from the ADDITION study showed that among individuals with normal glucose tolerance on an OGTT, those with HbA1c levels in the range 6.0-6.4% had 21% higher risk of all-cause mortality than those with HbA1c levels < 6.0% (23), again suggesting that HbA1c predicts mortality beyond fasting and 2-hour glucose levels. In relation to the use of FPG for diagnosis of pre-diabetes, results from meta-analyses have shown that pre-diabetes defined by the WHO IFG criterion, but not the ADA IFG criterion, is associated with increased risk of cardiovascular and all-cause mortality (24) . Similar results were found in relation to the risk of stroke (25) . A recent meta-analysis, however, concluded that IFG defined by the ADA criterion is associated with an increased risk of all-cause mortality, cardiovascular mortality, coronary heart disease and stroke (14) . However, a subgroup analysis revealed that among individuals aged 55 years or above ADA-defined IFG was not associated with all-cause mortality (14) . Combined with our results these findings suggest that the increased CVD and mortality risk associated with pre-diabetic FPG levels may decrease with age. It is thus likely that FPG is better for risk stratification in younger adults, whereas HbA1c is a better and more stable measure for health status in older adults, but this hypothesis needs to be tested in study populations with a wide age range. Part of the stronger association found between HbA1c and incident CVD may be explained by its capacity to reflect average glycaemia, but HbA1c may also indirectly capture information about other important pathophysiological processes such as iron metabolism and low-grade inflammation (26, 27) .
However, their causal effects need to be examined in more detail.
A major strength of the Whitehall II cohort is that the measures of FPG, 2hPG and HbA1c were obtained simultaneously and can be linked to validated measures of morbidity and mortality over a long follow-up period (20) . Deaths attributable to other causes than CVD were included in the analysis to avoid bias from competing risk. However, two out of three of the composite events were related to CVD, and sensitivity analyses with only CVD as outcome were consistent with our conclusions. Another strength of the current analysis is the application of all the different definitions for pre-diabetes. Most previous studies have only focused on a single definition of pre-diabetes (either WHO/IEC or ADA) and thereby used different reference groups for defining normoglycaemia (13, 23, 28) . Accordingly, event rates cannot be compared directly across studies to derive solid evidence on the association of pre-diabetes with morbidity and mortality. This could also explain why previous meta-analyses on the relationship of prediabetes with future morbidity and mortality have shown conflicting results (12, 13, 24, 25) . In the Whitehall II study, some individuals with pre-diabetes may develop diabetes during followup and subsequently receive treatment to reduce CVD risk. This could potentially have biased the results in the sense that the calculated event rates for WHO/IEC defined pre-diabetes are underestimated relative to the rates in ADA defined pre-diabetes, which have lower levels of glycaemia and therefore are less likely to convert to diabetes during follow-up. It is also possible that the way diabetes has been diagnosed by general practitioners between the study visits during follow up may have introduced bias. Before 2012, diabetes was mostly diagnosed by measurement of FPG levels, but after 2012 there has been a shift from FPG to HbA1c for diagnosis of diabetes in clinical practice in the UK (9). However, given that end of follow-up in our study was 30 th June 2015, we expect these effects to even out. Therefore, it is reasonable to believe that the differential associations of FPG versus HbA1c with CVD and mortality are not caused by diagnosis and treatment of diabetes and CVD risk in individuals identified by one specific diagnostic criterion over another during follow-up.
During the last decades there has been an increased focus on identifying high-risk individuals in order to prevent future disease and premature mortality. As a result, the diagnostic thresholds have been lowered for many diseases (29) , which has increased sensitivity at the cost of specificity. With the adoption of HbA1c as a diagnostic criterion for diabetes (9, 30) , the possibility of also using HbA1c to risk-stratify individuals for diabetes prevention is obvious, but the challenge is to choose the optimal cut-point. As shown in this and other studies (13, 28) , there does not seem to be an inflection point in the non-diabetic range for HbA1c in the association with CVD or mortality. Accordingly, when deciding on the diagnostic test and thresholds used to guide preventive interventions one needs to consider the effectiveness of interventions as well as the health and economic consequences of false-positives and falsenegatives (5, 31). The major diabetes prevention trials performed so far have included individuals with IGT and not people identified as having high risk by FPG or HbA1c (32) (33) (34) .
Despite the limited evidence for prevention in these groups of individuals, the current recommendations from ADA suggest that all individuals with pre-diabetes (IFG, IGT and/or HbA1c 5.7-6.4%) should be targeted for diabetes preventive efforts (lifestyle modification or metformin) (35). Because of the poor concordance between the different diagnostic criteria, it is questionable whether results from trials in IGT will apply to individuals identified by slightly elevated FPG or HbA1c levels. Thus, intervention studies among individuals identified by FPG or HbA1c aiming at reducing risk for diabetes and CVD are warranted in order to improve and modify the current recommendations (36) . More recent research also suggests that intermediate time points or different glucose curve patterns during an OGTT may be relevant to use for risk stratification purposes (37, 38) . Lastly, it will be important to evaluate pre-diabetes in the context of overall CVD risk, because of the close relationship of glycaemia with other cardiovascular risk factors. Thus, future risk prediction models should study whether easily measured risk factors and/or cheap biomarkers can jointly predict future diabetes, CVD and mortality.
In conclusion, our study showed that individuals with pre-diabetes defined using the ADA criteria have a lower risk of CVD and all-cause mortality than pre-diabetic individuals identified by the WHO/IEC criteria. This difference was mainly driven by the lower incidence of CVD or death among individuals with impaired fasting glucose but normal levels of HbA1c. Our results showed a high incidence rate of CVD and death in those with HbA1c levels 5.7-5.9%, which advocates for lowering the cut-point for pre-diabetes below that of 6.0% for CVD preventive interventions. That said, our study also shows that a substantial part of the excess risk in prediabetes is explained by other CVD risk factors, suggesting that the use of pre-diabetes as an independent factor for risk stratification is questionable. 
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